Follow The Filings

CABA Cabaletta Bio Inc.

Health Care, filed as CABALETTA BIO INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Bought by 1 manager in 2026 Q2

  • 1 Owner
  • Max 1.1%
  • $12M
  • 1 add

In 2026 Q2 James Silverman added to Cabaletta Bio.

Who owns this now

Largest portfolio weights among holders, up to 1.1% (James Silverman, Opaleye Management). Not free-float ownership.

  1. James Silverman Add 1.1%

Who owns CABA

Sorted by value, long equity only, as of 2026 Q2.

History
James Silverman, Opaleye Management 1.1%, was 0.49% Add +180.0% 3,863,800 $12M History

1 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by CABA's executives, directors and 10% owners in the last 12 months, from their Form 4s

All CABA insider trades
  • $296K bought by 8 insiders
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. David J. Chang Chief Medical Officer
    Buy
    $20K 8,800 shares at $2.26 New stake
    Traded Jan 21 Filed Jan 21
    ↗
  2. Gwendolyn Binder President, Science & Tech.
    Buy
    $25K 11,312 shares at $2.19 +57% to stake
    Traded Jan 21 Filed Jan 21
    ↗
  3. Shawn Tomasello Director
    Buy
    $50K 22,725 shares at $2.21 New stake
    Traded Jan 21 Filed Jan 21
    ↗
  4. Steve Gavel Chief Commercial Officer
    Buy
    $50K 22,170 shares at $2.27 New stake
    Traded Jan 21 Filed Jan 21
    ↗
  5. Catherine Bollard Director
    Buy
    $9,982 4,405 shares at $2.27 +441% to stake
    Traded Jan 21 Filed Jan 21
    ↗
  6. Steven Nichtberger CEO
    Buy
    $101K 45,000 shares at $2.24 +4.6% to stake
    Traded Jan 21 Filed Jan 21
    ↗
  7. Mark Simon Director
    Buy
    $25K 11,061 shares at $2.28 +8.1% to stake
    Traded Jan 21 Filed Jan 21
    ↗
  8. Michael Gerard General Counsel
    Buy
    $15K 6,600 shares at $2.27 New stake
    Traded Jan 21 Filed Jan 21
    ↗

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 8.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 5.03,5.07,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
DEFA14A Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 8.01,9.01 Filing Doc
424B5 Filing Doc
8-K 1.01,2.02,8.01,9.01 Filing Doc

Source: SEC EDGAR submissions, updated about 8 hours ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Net income -$67.68M -$115.86M -$167.86M

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $244.49M $166.68M $138.87M
Total non-current assets * $9.16M $18.37M $26.21M
Total assets $253.65M $185.05M $165.08M
Total current liabilities $15.99M $27.09M $50.15M
Total non-current liabilities * $1.46M $5.62M $2.88M
Total equity $236.2M $152.34M $112.05M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$53.55M -$88.22M -$131.08M
Cash from investing -$22.45M $47.29M -$50.27M
Cash from financing $187.63M $11.68M $100.35M
Net change in cash * $111.63M -$29.28M -$80.98M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.